Prof. Jiancheng Li 李建成
Chief Physician, Professor
Department of Radiation Oncology, Fujian Cancer Hospital, Fuzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy and comprehensive treatment for lung cancer, esophageal cancer, thymoma, and soft tissue tumors.
Dr. Li is Chief Physician and Professor at Fujian Medical University. Dr. Li studied at the University of Maryland and MD Anderson Cancer Center (2004–2005) and completed postdoctoral research in Florida (2012). Dr. Li has published over 80 papers and serves on editorial boards for journals including Chinese Journal of Cancer.
Professional roles
- Vice Chair, Esophageal Cancer Professional Committee, Fujian Anti-Cancer Association
- Standing Committee Member, Lung Cancer Professional Committee, Fujian Province
- Chair, Youth Committee, Lung Cancer Professional Committee, Fujian Province
- Vice Chair, Tumor Radiation Therapy Professional Committee, Fujian Anti-Cancer Association
Name order: in Chinese the family name comes first (Li Jiancheng). Papers usually list the name as Jiancheng Li or Li J.
Selected publications
82 papers on PubMed matched by name and affiliation; 44 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Med (Lausanne), 2026 (senior author): Retrospective analysis of postoperative adjuvant therapy and survival in T4 esophageal squamous cell carcinoma: a dual-cohort study using SEER and Chinese multicenter data. PubMed 41987784
- Nat Commun, 2025 (senior author): Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO). PubMed 41184224
- Front Immunol, 2025 (senior author): ZDHHC5 as a central regulator in a palmitoylation-associated prognostic model for lung adenocarcinoma: insights from pan-cancer and experimental analyses. PubMed 41058683
- Exp Cell Res, 2025 (senior author): Upregulation of Linc00960 promotes colorectal cancer cell proliferation by regulating hsa-miR-107/CDK6 axis. PubMed 40780387
- BMC Cancer, 2024 (senior author): Prospective multicenter study of camrelizumab in real-world settings for asian patients with esophageal squamous cell carcinoma. PubMed 39558325
- Front Oncol, 2024 (senior author): A nomogram with Nottingham prognostic index for predicting locoregional recurrence in breast cancer patients. PubMed 39351357
- J Gastrointest Oncol, 2024 (senior author): Prognosis for local radical treatment in patients with esophageal squamous cell carcinoma with low-risk oligometastatic recurrence after curative resection: a retrospective cohort study. PubMed 38989428
- Heliyon, 2024 (senior author): Mitochondrial ribosomal protein S24 is associated with immunosuppressive microenvironment and cold tumor in lung adenocarcinoma. PubMed 38617968
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion